3.2 Survival
A relapse or progressive disease was noted in 11 (39%) patients at a median duration of 17 months (IQR: 5, 18). Following the completion of therapy, 2 (7%) patients died at home at 21 and 31 months of follow up. The cause of death could not be ascertained. Two patients discontinued follow up at 12 and 21 months; they were non-contactable and were censored at the point of the last contact. Nine patients are alive at a median duration of 49 months (IQR: 45, 79). Two (50%) patients who had a VGPR and 7 (41%) patients with PR are alive. No patient who had MR or PD survived. Of the 9 patients who are alive, surgery was performed in all except one, in whom the primary, following rapid COJEC, had reduced to size, considered too small for resection. The extent of surgical resection in survivors was complete in 2, and debulking in 6. The 4-year overall survival (OS), as well as event-free survival (EFS) of patients (n=28), was 29.3% (Fig. 3).